Suppr超能文献

基于饱和聚甘油化甘油酯的吲哚美辛单一片剂、零级缓释硬明胶胶囊制剂的体内评价

In vivo evaluation of an indomethacin monolithic, extended zero-order release hard-gelatin capsule formulation based on saturated polyglycolysed glycerides.

作者信息

Vial-Bernasconi A C, Buri P, Doelker E, Beyssac E, Duchaix G, Aiache J M

机构信息

Laboratoire de Pharmacie Galénique, Université de Genéve, Switzerland.

出版信息

Pharm Acta Helv. 1995 Dec;70(4):307-13. doi: 10.1016/0031-6865(95)00036-4.

Abstract

The sustained release properties of an indomethacin hard-gelatin capsule formulated with saturated polyglycolysed glycerides (Gelucire) were demonstrated in vivo. Indomethacin was selected as a model drug with very poor solubility in water and acidic media. It is known to exhibit high intersubject variability because of enterohepatic circulation. The formulation, which in vitro showed an erosion-controlled release, was compared in six human volunteers in the fed state by using a randomized cross-over design, to a standard multiple-unit diffusion-controlled pellet capsule. Close action period values (time duration with plasma levels higher than 0.5 micrograms/ml) were found for the test and the reference formulation (5.2 and 5.7 h). The time to reach peak t(max) appeared slightly shorter for the test preparation (1.75 h) than for the reference formulation (2.67 h), but the difference was not statistically significant because of the high intersubject variability (non-parametric Wilcoxon matched pair test). Again, due to the small number of subjects entered in the study (insufficient for a real bioequivalence study) equivalence could not be accepted in terms of extent and rate of absorption based on the decision procedures involving the 90% confidence interval and the two one-sided t-tests. The mean maximum plasma concentrations Cmax were 3.35 and 2.82 micrograms/ml for the test and the reference formulation respectively, with the corresponding values of the area under the plasma concentration-time curve AUC amounting to 10.14 and 11.38 micrograms h/ml. However, a simulation on 24 subjects (3 repetitions of the same data) would lead to bioequivalence of the two preparations. As for other corrosion-controlled forms, drug release from the proposed Gelucire formulation was very sensitive to hydrodynamic conditions, leading to poor in vitro-in vivo correlation, when comparison is made with a reference formulation characterized by a diffusion-controlled release. Finally, it was concluded that erosion-controlled release formulations are especially suitable for drugs, such as indomethacin, that have low solubility in water or acidic media. More generally, sustained release hard gelatin capsules with thermosetting excipients is very versatile and their preparation is very straightforward.

摘要

用饱和聚甘油化甘油酯(Gelucire)制备的吲哚美辛硬明胶胶囊的体内缓释特性得到了证实。吲哚美辛被选为在水和酸性介质中溶解度非常低的模型药物。由于肠肝循环,已知其个体间变异性较高。该制剂在体外显示出溶蚀控制释放,通过随机交叉设计在六名处于进食状态的人类志愿者中与标准多单元扩散控制微丸胶囊进行了比较。测试制剂和参比制剂的近作用期值(血浆水平高于0.5微克/毫升的持续时间)分别为5.2小时和5.7小时。测试制剂达到峰值的时间(t(max))(1.75小时)似乎比参比制剂(2.67小时)略短,但由于个体间变异性高(非参数Wilcoxon配对检验),差异无统计学意义。同样,由于纳入研究的受试者数量较少(不足以进行真正的生物等效性研究),基于涉及90%置信区间和两个单侧t检验的决策程序,在吸收程度和速率方面不能接受等效性。测试制剂和参比制剂的平均最大血浆浓度(Cmax)分别为3.35微克/毫升和2.82微克/毫升,血浆浓度-时间曲线下面积(AUC)的相应值分别为10.14微克·小时/毫升和11.38微克·小时/毫升。然而,对24名受试者(相同数据重复3次)进行模拟会得出两种制剂生物等效的结论。与其他溶蚀控制剂型一样,当与以扩散控制释放为特征的参比制剂相比时,所提出的Gelucire制剂的药物释放对流体动力学条件非常敏感,导致体外-体内相关性较差。最后得出结论,溶蚀控制释放制剂特别适用于在水或酸性介质中溶解度低的药物,如吲哚美辛。更一般地说,具有热固性辅料的缓释硬明胶胶囊非常通用,其制备非常简单。

相似文献

引用本文的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验